These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 1608663)

  • 1. [Cholecystokinin antagonists: anxiolytic drugs of the future].
    Bourin M; Bradwejn J
    Pathol Biol (Paris); 1992 Mar; 40(3):215-7. PubMed ID: 1608663
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
    Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cholecystokinin and its antagonists: effects on digestive motility].
    Bruley des Varannes S; Cloarec D; Dubois A; Galmiche JP
    Gastroenterol Clin Biol; 1991; 15(10):744-57. PubMed ID: 1816015
    [No Abstract]   [Full Text] [Related]  

  • 4. [Gastrin-/CCK-B antagonists are neuropharmacological tools].
    Oreland L
    Lakartidningen; 1995 Feb; 92(6):531-2. PubMed ID: 7853937
    [No Abstract]   [Full Text] [Related]  

  • 5. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.
    Rataud J; Darche F; Piot O; Stutzmann JM; Böhme GA; Blanchard JC
    Brain Res; 1991 May; 548(1-2):315-7. PubMed ID: 1868342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J; Koszycki D
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of cholecystokinin receptor antagonists in CNS disorders.
    Schiantarelli P
    Pharmacol Res; 1993; 28(1):1-9. PubMed ID: 8234141
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential effects of benzodiazepines, including diazepam, clonazepam, Ro 5-4864 and devazepide, on lindane-induced toxicity.
    Woolley DE
    Proc West Pharmacol Soc; 1994; 37():131-4. PubMed ID: 7527152
    [No Abstract]   [Full Text] [Related]  

  • 9. Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist.
    Wolkowitz OM; Gertz B; Weingartner H; Beccaria L; Thompson K; Liddle RA
    Biol Psychiatry; 1990 Jul; 28(2):169-73. PubMed ID: 2378921
    [No Abstract]   [Full Text] [Related]  

  • 10. Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists.
    Kerwin JF; Nadzan AM; Kopecka H; Lin CW; Miller T; Witte D; Burt S
    J Med Chem; 1989 Apr; 32(4):739-42. PubMed ID: 2704023
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of cholecystokinin in the pathogenesis of acute pancreatitis in the isolated pancreas preparation.
    Nordback IH; Clemens JA; Cameron JL
    Surgery; 1991 Mar; 109(3 Pt 1):301-6. PubMed ID: 1705726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
    van Megen HJ; Westenberg HG; den Boer JA
    Biol Psychiatry; 1996 Oct; 40(8):804-6. PubMed ID: 8894076
    [No Abstract]   [Full Text] [Related]  

  • 13. The cholecystokinin hypothesis of anxiety and panic disorder.
    Bradwejn J; Koszycki D
    Ann N Y Acad Sci; 1994 Mar; 713():273-82. PubMed ID: 8185169
    [No Abstract]   [Full Text] [Related]  

  • 14. CCK agonists and antagonists in clinical studies of panic and anxiety.
    Bradwejn J
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():481A-482A. PubMed ID: 1498920
    [No Abstract]   [Full Text] [Related]  

  • 15. The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey.
    Dourish CT; O'Neill MF; Schaffer LW; Siegl PK; Iversen SD
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1158-65. PubMed ID: 2262899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder.
    Brawman-Mintzer O; Lydiard RB; Bradwejn J; Villarreal G; Knapp R; Emmanuel N; Ware MR; He Q; Ballenger JC
    Am J Psychiatry; 1997 May; 154(5):700-2. PubMed ID: 9137133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the significance of cholecystokinin receptors in panic disorder.
    van Megen HJ; den Boer JA; Westenberg HG
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1235-46. PubMed ID: 7863014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cholecystokinin receptor blockade on human lymphocyte proliferation.
    Ferrara A; McMillen MA; Schaefer HC; Zucker KA; Modlin IM
    J Surg Res; 1990 Apr; 48(4):354-7. PubMed ID: 2338822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin receptor antagonists.
    Zucker KA; Adrian TE; Modlin IM
    J Surg Res; 1988 Nov; 45(5):496-504. PubMed ID: 3054325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.